Słuczanowska-GłąbowskaSZiegler-KrawczykASzumilasKPawlikA.Role of Janus kinase inhibitors in therapy of psoriasis. J Clin Med. 2021;10(19):4307. doi:10.3390/jcm10194307
2.
RichPScherRK.Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206-212. doi:10.1067/s0190-9622(03)00910-1
3.
PaulCCatherJGooderhamM, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387-1399. doi:10.1111/bjd.14164
4.
HwangJKGroverCIorizzoM, et al. Nail psoriasis and nail lichen planus: updates on diagnosis and management. J Am Acad Dermatol. 2023;90(3):585-596. doi:10.1016/j.jaad.2023.11.024
5.
LowesMARussellCBMartinDATowneJEKruegerJG.The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174-181. doi:10.1016/j.it.2012.11.005
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
